Calciphylaxis
18
5
5
7
Key Insights
Highlights
Success Rate
78% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
11.1%
2 terminated out of 18 trials
77.8%
-8.7% vs benchmark
28%
5 trials in Phase 3/4
29%
2 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (18)
Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications
Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis
Better Evidence and Translation for Calciphylaxis
A Real-World Registry of Chronic Wounds and Ulcers
Double-blind Trial of Sodium Thiosulfate for the Treatment of Pain Associated With Calcific Uremic Arteriolopathy
The SEAPORT 1 Study: Evaluation of the Safety and Tolerability of INZ-701 in Adults With End-Stage Kidney Disease Undergoing Hemodialysis
Partners Calciphylaxis Biobank
Phase 3 Study of SNF472 for Calciphylaxis
National Registry of Rare Kidney Diseases
Calciphylaxis : Population, Risk Factors, Diagnostic Practice, Therapeutic and Outcome
Pathophysiology of Martorell Hypertensive Ischemic Leg Ulcer (HYTILU)
A Phase 3 Clinical Trial of Intravenous Sodium Thiosulfate in Acute Calciphylaxis Patients
Evaluation of Vitamin K Supplementation for Calcific Uremic Arteriolopathy
Phase 2 Study With SNF472 in Calciphylaxis Patients
Observational Follow-up to ST-001 Calciphylaxis Pain Treatment With Intravenous Sodium Thiosulfate
The Early Administration of Sodium Thiosulfate Should Help to Reduce the Mortality of Dialysis Patients With Calciphylaxis, From a National Cohort
European Calciphylaxis Registry Network
Efficacy of Lanthanum Carbonate in Calciphylaxis